儿童C3肾小球病与免疫复合物相关膜增生性肾小球肾炎的自然病史
本研究利用PEDSnet多机构电子健康记录数据,通过可计算表型算法识别儿童膜增生性肾小球肾炎队列,并分类为C3G或IC-MPGN。结果显示两组在基线蛋白尿、低白蛋白血症、高血压和低补体血症程度相似,进展至复合肾脏结局(eGFR下降50%、透析或移植)的速率也相似,且基线低C3水平与复合结局相关。
要点
- 儿童C3G与IC-MPGN基线临床特征和进展速率相似。
- 基线低血清C3水平与复合肾脏结局相关。
- 新型补体靶向药物可能对该人群有益。
核心结论
- 儿童C3G与IC-MPGN的基线临床特征和进展至复合肾脏结局的速率相似。
- 基线低血清C3水平与达到复合肾脏结局相关。
研究设计与样本
- 利用PEDSnet七个机构的电子健康记录数据,通过可计算表型算法识别儿童C3G或IC-MPGN队列。
- 从电子健康记录中提取离散数据元素,并由儿科肾脏病专家通过标准化病历审查提取额外临床和病理数据。
- 通过基于免疫荧光和电镜的算法结合人工病历审查将活检诊断分类为C3G或IC-MPGN。
- 使用Kaplan-Meier生存曲线比较达到复合肾脏结局(eGFR下降50%、开始维持性透析或肾移植)的风险。
主要发现
- 可计算表型算法和病历审查识别出204例膜增生性肾小球肾炎患者,其中159例可根据活检数据进一步分类为C3G或IC-MPGN。
- C3G与IC-MPGN在基线血清白蛋白、C3水平、尿蛋白/肌酐比值或eGFR方面无显著差异。
- C3G和IC-MPGN患者进展至复合肾脏结局的速率相似,且基线低血清C3水平与该复合结局相关。
临床怎么用
- 对于儿童C3G和IC-MPGN,应认识到两者均具有进展至 kidney failure 的风险,且基线低C3提示更高风险。
- 尽管缺乏靶向治疗,但新型补体靶向药物可能为这类患者带来获益。
局限性
- 本研究为基于电子健康记录的多机构回顾性队列研究,可能存在数据缺失或分类不准确。
- 仅159例患者可分类为C3G或IC-MPGN,样本量有限。
- 未报告具体的统计显著性检验结果(如P值)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: C3 glomerulopathy and immune complex-associated membranoproliferative glomerulonephritis in children have similar degrees of proteinuria, hypoalbuminemia, hypertension, and hypocomplementemia at diagnosis. C3 glomerulopathy and immune complex-associated membranoproliferative glomerulonephritis in children progress similarly to a composite outcome of CKD, dialysis, or kidney transplantation. A low level of C3 at baseline is associated with achieving the composite outcome. BACKGROUND: C3 glomerulopathy (C3G) and immune complex-associated membranoproliferative glomerulonephritis (IC-MPGN) are rare complement-mediated kidney diseases with a high risk of progression to kidney failure. Little is known about the natural history of these diseases in children, limiting our understanding of risk factors for progressive kidney disease. METHODS: Using a computable phenotype algorithm, a pediatric cohort with C3G or IC-MPGN was identified at seven institutions in PEDSnet, a national network of pediatric health systems which aggregate electronic health record data and collaborate on pragmatic research studies. Discrete data elements were captured from electronic health records, and additional clinical and histopathologic data were extracted by standardized chart review by pediatric nephrologists. Biopsy diagnosis was classified as C3G or IC-MPGN by applying an algorithm on the basis of immunofluorescence and electron microscopy and supplemented with manual chart review. Kaplan-Meier survival curves were used to compare the risk of reaching a composite kidney outcome of 50% reduction in eGFR, initiation of maintenance dialysis, or kidney transplantation. RESULTS: Of 204 patients with membranoproliferative glomerulonephritis identified by the computable phenotype algorithm and chart review, 159 could be further classified as C3G or IC-MPGN on the basis of available biopsy data. There were no significant differences in baseline serum albumin, C3 level, urine protein/creatinine ratio, or eGFR between C3G and IC-MPGN. Patients with C3G and IC-MPGN had similar rates of progression to the composite kidney outcome, and a low serum C3 level at baseline was associated with this composite outcome. CONCLUSION: Using large-scale, real-world multi-institutional data, we investigated the natural history of a large contemporary cohort of children with membranoproliferative glomerulonephritis. Because patients classified as having C3G compared with IC-MPGN had similar baseline clinical characteristics and rates of progressive disease despite untargeted treatment approaches, the availability of newer complement-targeted agents hold the promise of benefit to this population.
引用
- Dixon BP, Laskin BL, Goodwin Davies AJ, et al. Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children. Clin J Am Soc Nephrol. 2026. PMID: 42329702. doi:10.2215/CJN.0000001118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。